Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS3 | P29474 | 3/20 | 0.47 |
| ▸ | NOS2 | P35228 | 3/20 | 0.47 |
| ▸ | KMO | O15229 | 2/20 | 0.43 |
| ▸ | NISCH | Q9Y2I1 | 1/20 | 0.42 |
| ▸ | ALOX5AP | P20292 | 2/20 | 0.39 |
| ▸ | FEN1 | P39748 | 2/20 | 0.39 |
| ▸ | EPHB4 | P54760 | 1/20 | 0.39 |
| ▸ | ABL1 | P00519 | 2/20 | 0.38 |
| ▸ | AKR1C3 | P42330 | 2/20 | 0.38 |
| ▸ | AKR1C2 | P52895 | 2/20 | 0.38 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.36 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.36 |
| ▸ | ADK | P55263 | 1/20 | 0.36 |
| ▸ | AKR1B10 | O60218 | 1/20 | 0.36 |
| ▸ | AKR1C4 | P17516 | 1/20 | 0.36 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.36 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.36 |
| ▸ | DHFR | P00374 | 1/20 | 0.35 |
| ▸ | NOS1 | P29475 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17660346 | 0.80 | ALOX5AP (0.42) | NOS3NOS2ALOX5APFEN1EPHB4 | |
| SCHEMBL17670765 | 0.78 | BTK (0.41) | NOS3NOS2ALOX5APFEN1EPHB4 | |
| SCHEMBL13506871 | 0.78 | NOS3 (0.41) | NOS3NOS2NISCHEPHB4 | |
| SCHEMBL18474589 | 0.77 | NOS3 (0.43) | NOS3NOS2NOS1 | |
| SCHEMBL17555726 | 0.77 | FYN (0.49) | KMO | |
| SCHEMBL17670764 | 0.76 | MAPK1 (0.45) | ALOX5APFEN1 | |
| SCHEMBL13730604 | 0.75 | NOS3 (0.52) | NOS3NOS2NOS1 | |
| SCHEMBL17555671 | 0.75 | CDK2 (0.43) | NOS3NOS2ABL1 | |
| SCHEMBL11901043 | 0.73 | MAP4K4 (0.48) | NOS3NOS2KMOABL1NOS1 | |
| SCHEMBL17645746 | 0.73 | BTK (0.41) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8648075-B2 | Substituted pyrido[2,3-b]pyrazines and an agrochemical composition thereof | KUMIAI CHEMICAL INDUSTRY CO., LTD. (JP) | 2014-02-11 | — | — | US | disclosed |
| US-20130137577-A1 | OXOPYRAZINE DERIVATIVE AND HERBICIDE | IHARA CHEMICAL INDUSTRY CO., LTD. (JP) | 2013-05-30 | — | — | US | disclosed |
| US-8389523-B2 | Substituted quinoxaline and an agrochemical composition thereof | KUMIAI CHEMICAL INDUSTRY CO., LTD. (JP) | 2013-03-05 | — | — | US | disclosed |
| EP-2174934-B1 | OXOPYRAZINE DERIVATIVE AND HERBICIDE | KUMIAI CHEMICAL INDUSTRY CO (JP) | 2012-06-06 | — | — | EP | disclosed |
| US-20100197674-A1 | OXOPYRAZINE DERIVATIVE AND HERBICIDE | KUMIAI CHEMICAL INDUSTRY CO., LTD. (JP) | 2010-08-05 | — | — | US | disclosed |
| EP-2174934-A1 | OXOPYRAZINE DERIVATIVE AND HERBICIDE | KUMIAI CHEMICAL INDUSTRY CO., LTD. (JP) | 2010-04-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130137577-A1 | OXOPYRAZINE DERIVATIVE AND HERBICIDE | CBR3, CBR1, DDT | NOS3 125/4885NOS2 254/4885KMO 1405/4885 |
| US-20100197674-A1 | OXOPYRAZINE DERIVATIVE AND HERBICIDE | CBR3, CBR1, DDT | NOS3 125/4885NOS2 254/4885KMO 1405/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.